Edition: October 2014

Size: px

Start display at page:

Download "Edition: October 2014"

Sydney Gordon
5 years ago
Views:

2 Edition: October 2014 Monday s Flashnews (unedited copy) Though you might conquer in battle A thousand times a thousand men, You're the greatest battle-winner If you conquer just one - yourself. Dear Members, I reached India and will be busy here for two weeks. We will be sending our Weekly and Daily Flash news at different or delated times because of the time difference so please bear with us. We received a few s asking whether the sharp fall in the market and after huge corrections what was the main reason why the markets bounced back sharply, s it a false rise? We always stated that we don t pay attention to sharp falls or rise, and neither do we pay attention to the media headlines or what experts are saying because all this will confuse us and we won t be able to guide you correctly. One learned man said: We don t need to conquer the world, we just need yes it is a very important quote. We are not at war but we trade and invest in the markets, and according to me it is the most difficult job. People think that trading or investment is just an easy and boring job. When I start writing the weekly letter, I have to keep my focus on only one thing; and that is what is coming next in the astro cycle, and I have to trust those indicators. My members have to do same thing; they have to plan their strategy, they have to trust their strategy and they have to build confidence in what they doing, where they investing, and in what they are investing because I am just giving you the overall outline and the rest is up to you. If you don t trust our letter then you don t need to subscribe to it because it won t help you, you have to plan your strategy with our letter and see which is working better for you. One thing I am aware of is that you can make a lot of money with high leverage trading (in a bull or a bear market), if you are in right side but if you re on the wrong side then the market can just throw you out. Stock Investment Report Page 2

3 I have been trading in the market since I was 17 (or since 1985), and let me tell you that the astro cycles are great hidden tools which can help us to plan our investment strategy very well. The last 9 trading days have proven to be amazing for investors because S&P bounced back from 1813 to 1960, this was one of the best gains in many years. We felt like there was a huge move on the way, in fact I sent a mid-day alert that Dow is ready to rise 1000 points. Who else predicted this kind of move? Even if anyone knew this they wouldn t risk doing it during an uncertain scenario because they don't want to be wrong. This just goes to show how much I trust the astro cycle. In the last twenty years the astro cycles have guided us very accurately on many crucial occasions. From 2001 we started writing very bullish predictions for gold, and we kept recommending investors to buy gold. In 2004/5 gold fell below $400 and we predicted that we wouldn't see these prices again but investors remained skeptical because the fall came very sharply. We were confident of gold reaching $1600 to $1800 and topping out around that level. Yes gold topped out in 2011 above $1800 and since then prices have been falling. We were lucky to predict the bottom and top for the gold market. Our astro cycles have been able to provide us with the bottom and top in oil, euro and in most other markets. We are very confident about S&P reaching 3200 but we would like to watch Saturn s transit which will take place in the month of November. If Saturn plays a positive role then we expect S&P to reach 5000 within next 30 months. This indicates that huge changes will come in investment strategy from big guys, banks, financial institutions as well as central banks otherwise how this huge move will be possible. Tulip mania or a bigger phenomenon than Tulip mania could be possible on Wall-Street according to what we see but we will wait to see what this Saturn is up to. Wait for another three weeks to get our answer from us about whether S&P is reaching 5000 in 30 months. After the last week performance we clearly getting indications that biotech stocks are ready to enter in fourth bullish cycle and after this one another three are pending. In the last two years we constantly recommending buying as well as holding positions in the biotech stocks and we are still recommending strongly to invest in this sector. Our most favourite stocks from here are: ACHC: This in not biotech stock, it is hospital and health service stock. We recommended buying ACHC during last year and we still recommend holding position in it. Our conservative target is $70.00 by end of next year. PCRX: This stock performed very well since our recommendations and we are still recommending adding on weakness. Our target is $138 by end of next year. REGN: This one achieved our 2014 target, now we raise our target to $520 by end of next year. Keep adding on any weakness. Stock Investment Report Page 3

4 PCYC: This is also we recommended last year and we are still recommending to add more positions in it. Our target $170 by end of next year. ACT: Performed well, and should performing well in 2015, our new target for this one is $270 by the end of next year. MDVN: Performed well in 2014, we are still recommending to add even cat current price. Our target is $135 by end of next year. Rest recommended like HZNP, AEGR, GILD, CLEG, AMGN, BIIB, CLDX, BCRX, LGND, ALXN, THC and BMY. This week many tech and biotech companies will be releasing earnings as many requested to put out short term trade as well so here are buying list of this week for short term traders for this week: ACHC (Friday s clos is $52.90), ARII (Friday s clos is $42.00)), BIDU (Friday s clos is $122.00), THRM (Friday s clos is $42.40), PCRX (Friday s clos is $106.20), and PCYC (Friday s clos is $123.00). Buy this week Fridays call options and get out next day of earning, these stocks are also good for medium and longer term. At this stage we don t see S&P going below 1937 (even if European bank stress test comes negative which we don t see happening, we are expecting mix result from stress test), so this level should be taken as a buying opportunity. Now once again 1988 is coming closer. This level proven to be a very strong astro resistance level so watch it closely. S&P has to close above 1988 for seven days to confirm that it is moving towards Many will say that why haven t I mentioned 2130 figure because it is important of S&P close above 1988 for five days then it will rise like a wild fire. We are adding one more stock in our favourite buying list: INCY: Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary small molecule drugs primarily for oncology and inflammation. The company markets JAKAFI, an oral janus associated kinase (JAK) inhibitor for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF. Its product pipe line includes ruxolitinib, a JAK inhibitor, which is in Phase III clinical trial for polycythemia vera; in Phase II trial for pancreatic cancer; and in Phase I trial for the treatment of malignancies, as well as baricitinib, a JAK inhibitor, which is in Phase III trial for rheumatoid arthritis, in Phase IIb trial for psoriasis, and in Phase II trial for diabetic nephropathy. The company s products in pipeline also comprise INC280, which is in Phase II clinical trial for the treatment of solid tumors, hepatocellular carcinoma, and non-small cell lung cancer; and INCB24360 that is in Phase II clinical trial for the treatment of metastatic melanoma and ovarian cancer; INCB40093 and INCB39110+INCB40093, which are Phase I clinical trial Stock Investment Report Page 4

products for the treatment of B-lymphoid malignancies; INCB39110 that is in Phase II for myelofibrosis treatment and in Phase I for the treatment of malignancies; and INCB47986, which is in Phase I

5 products for the treatment of B-lymphoid malignancies; INCB39110 that is in Phase II for myelofibrosis treatment and in Phase I for the treatment of malignancies; and INCB47986, which is in Phase I clinical trial products for the treatment of rheumatoid arthritis. It has a collaborative research and license agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; and Pfizer Inc., as well as strategic collaboration arrangement with Merck. The company was founded in 1991 and is headquartered in Wilmington, Delaware. This is what we mentioned yesterday: S&P closed above 1907 for two days which clearly indicating bullish trend for market from mid-day tomorrow. This is what we mentioned on Monday, and must read one more time: Weekend changed in planetary positions supported on Monday which is great sign. If S&P close above 1907 for two days will confirm huge upside movement coming soon and expect market to move sharply higher toward This is what we mentioned Tuesday: Wednesday short term traders should book profit but one should buy back on lower side as if S&P holds 1918 level. On Monday we mentioned that S&P would rock if it trade two days above 1918 which may take S&P toward 2000 level. This is what we mentioned yesterday and we would like you to read one more time: If we are right on this then watch market because DOW is ready to move 500 to 700 to even 1000 point rally in day. I have trusted our astro indicators in the last 25 years, and they never guided us wrong on crucial stage. We saw this uncertainty coming for short period from 19 September to 16 October, we are 48 hours away from 16 Oct but this Mars can make everyone crazy. Though we would like to stay remain bit cautious until 23 to 27 October, but our lower side target of S&P 1856 is just 10 point away so we won t like to wait for longer period. Daily Trading ranges for Monday (Indexes range are December future contracts): Stock Investment Report Page 5

6 S&P TO NASDAQ TO RUSSELL TO DOW TO Amazon: to AAPL: TO GOOGLE: $ to Goldman: to GMCR: to YHOO: to CMG: to COSTCO: to Microsoft: to NETFLIX: to REGN: to GILD: to AMGN: to CELG: to BIIB: to Thanks & God Bless, Mahendra Sharma, 26 October 2014, AM, Mumbai This is what we mentioned on 29 September: I have been watching very closely our few recommendations of ETF, So far DUST, JDST, GLL, DSLV, FAS and DRN performed well. Stock Investment Report Page 6

7 Few more ETF s should be watch closely and most favorite is TMV, we see positive trend. Also currently some volatility have back in market so one can take small hedging position in UVXY. In correction in market can push UVXY sharply higher so great hedging trade. We don t see any fear or weaker trend in market after 25 October, it will be one side rally throughout year end. We still believe S&P may move toward 2130 and Nasdaq Just take care of next three weeks and I am sure your yearend will be very exciting one. Astro indicators are not showing any negativity, and if Mars starts playing a role then US market can go wild for the next month. Historically, October has proven that it is a damaging month because Sun transits from Virgo to Libra (according to Vedic astro cycle) and Sun brings big fear. Let s see whether Mars takes control this time or not. In medium term Keurig Green Mountain (GMCR) coffee looks great bet, this stocks can easily move toward $250 level by end on next year so don t miss opportunity of buying. Tow week back we strongly recommended buying around $115, currently trading around $135. Make wave of nature/astronomical cycle an integral part of your trading/investment strategies! Reading daily range: When we predict a weaker trend it means prices can break lower side and they can trade below predicted lows. (You can cover short but don t buy extra at lower levels until our indicators give buy signal). When we predict a positive trend, means daily price can break upside and they can trade higher than predicted price (you can book profit but don t short that market). Copyrights: We have just updated the copyrights of our work on, under the USA and under international laws. There will be heavy penalties and legal charges against individuals, groups or firms who are copying, editing or forwarding our work in any form without authorized permission. Members or Subscribers of mahendraprophecy.com should do their own research and due diligence before investing in any of recommendations. Investing in stocks, futures and options is very speculative and carries a high amount of risk. Subscriber may lose money trading and investing in such investment. Stock Investment Report Page 7

Monday s trading range for Stocks & Indexes (Unedited copy)

Edition: 541 22 July 2014 Monday s trading range for Stocks & Indexes (Unedited copy) Dear Members, On Monday traders remained very cautious due to geo-politics tensions also on other hand USA investors